AJOONIAnimal Feed
Ajooni Biotech Ltd — Profit & Loss Statement
₹3.84
-3.98%
Ajooni Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -7456.37 | -0.07 Cr | — |
| Tax Rate For Calcs | 0.22 | 0.28 | 0.29 | 0.28 | — |
| Normalized EBITDA | 5.76 Cr | 4.43 Cr | 3.05 Cr | 3.23 Cr | — |
| EBITDA | 5.76 Cr | 4.43 Cr | 3.05 Cr | 2.97 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Reconciled Depreciation | 1.09 Cr | 0.87 Cr | 1.00 Cr | 0.97 Cr | — |
| Reconciled Cost Of Revenue | 97.03 Cr | 70.35 Cr | 65.74 Cr | 64.01 Cr | — |
| EBIT | 4.66 Cr | 3.55 Cr | 2.05 Cr | 2.00 Cr | — |
| Net Interest Income | -0.33 Cr | -0.56 Cr | -0.27 Cr | -0.54 Cr | — |
| Interest Expense | 0.33 Cr | 0.56 Cr | 0.47 Cr | 0.54 Cr | — |
| Normalized Income | 3.37 Cr | 2.16 Cr | 1.13 Cr | 1.24 Cr | — |
| Net Income From Continuing And Discontinued Operation | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Total Expenses | 112.10 Cr | 78.75 Cr | 72.72 Cr | 71.81 Cr | — |
| Diluted NI Availto Com Stockholders | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Net Income Common Stockholders | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Net Income Including Noncontrolling Interests | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Net Income Continuous Operations | 3.37 Cr | 2.16 Cr | 1.12 Cr | 1.05 Cr | — |
| Tax Provision | 0.96 Cr | 0.83 Cr | 0.45 Cr | 0.41 Cr | — |
| Pretax Income | 4.33 Cr | 3.00 Cr | 1.58 Cr | 1.46 Cr | — |
| Other Non Operating Income Expenses | 2.07 Cr | 2.19 Cr | 0.09 Cr | 0.04 Cr | — |
| Net Non Operating Interest Income Expense | -0.33 Cr | -0.56 Cr | -0.27 Cr | -0.54 Cr | — |
| Interest Expense Non Operating | 0.33 Cr | 0.56 Cr | 0.47 Cr | 0.54 Cr | — |
| Operating Income | 2.59 Cr | 1.36 Cr | 1.76 Cr | 2.22 Cr | — |
| Operating Expense | 15.07 Cr | 8.40 Cr | 6.98 Cr | 7.80 Cr | — |
| Other Operating Expenses | 11.22 Cr | 5.73 Cr | 1.34 Cr | 1.90 Cr | — |
| Depreciation And Amortization In Income Statement | 1.09 Cr | 0.87 Cr | 1.00 Cr | 0.97 Cr | — |
| Depreciation Income Statement | 1.09 Cr | 0.87 Cr | 1.00 Cr | 0.97 Cr | — |
| Gross Profit | 17.66 Cr | 9.76 Cr | 8.74 Cr | 10.02 Cr | — |
| Cost Of Revenue | 97.03 Cr | 70.35 Cr | 65.74 Cr | 64.01 Cr | — |
| Total Revenue | 114.69 Cr | 80.11 Cr | 74.49 Cr | 74.04 Cr | — |
| Operating Revenue | 114.69 Cr | 80.11 Cr | 74.49 Cr | 74.04 Cr | — |
| Total Unusual Items | — | 1.31 Cr | -26000.00 | -0.26 Cr | -0.14 Cr |
| Total Unusual Items Excluding Goodwill | — | 1.31 Cr | -26000.00 | -0.26 Cr | -0.14 Cr |
| Interest Income | — | 0.50 Cr | 0.20 Cr | 6000.00 | 2137.00 |
| Rent Expense Supplemental | — | 0.12 Cr | 0.10 Cr | 0.13 Cr | 0.08 Cr |
| Diluted Average Shares | — | 8.64 Cr | 0.75 Cr | 6.50 Cr | 6.43 Cr |
| Basic Average Shares | — | 8.64 Cr | 0.75 Cr | 6.50 Cr | 6.43 Cr |
| Diluted EPS | — | 0.25 | 1.51 | 0.16 | 0.06 |
| Basic EPS | — | 0.25 | 1.51 | 0.16 | 0.06 |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | — |
| Special Income Charges | — | 1.31 Cr | -26000.00 | -0.26 Cr | -0.14 Cr |
| Other Special Charges | — | -1.31 Cr | 1000.00 | 0.01 Cr | 11000.00 |
| Write Off | — | 0.00 | 25000.00 | 0.25 Cr | 0.14 Cr |
| Total Other Finance Cost | — | 82000.00 | 97000.00 | 11000.00 | 0.09 Cr |
| Interest Income Non Operating | — | 0.50 Cr | 0.20 Cr | 6000.00 | 2137.00 |
| Research And Development | — | 0.07 Cr | 0.24 Cr | 0.05 Cr | 0.07 Cr |
| Selling General And Administration | — | 3.24 Cr | 2.05 Cr | 2.88 Cr | 3.20 Cr |
| Selling And Marketing Expense | — | 2.45 Cr | 1.51 Cr | 2.53 Cr | 2.72 Cr |
| General And Administrative Expense | — | 0.79 Cr | 0.54 Cr | 0.35 Cr | 0.48 Cr |
| Rent And Landing Fees | — | 0.12 Cr | 0.10 Cr | 0.13 Cr | 0.08 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ajooni Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.